RNAi-mediated gene silencing in non-human primates. - Wikidata - awgldk - TriplyDB

RNAi-mediated gene silencing in non-human primates.

RNAi-mediated gene silencing in non-human primates.

http://www.wikidata.org/entity/Q53630565

about

RNAa is conserved in mammalian cells Oligonucleotide therapeutic approaches for Huntington disease Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics Genomic screening with RNAi: results and challenges Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates The promises and pitfalls of RNA-interference-based therapeutics Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?lncRNA/MicroRNA interactions in the vasculature Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis RNA mediated Toll-like receptor stimulation in health and disease Delivery of gene silencing agents for breast cancer therapy Delivery of oligonucleotides with lipid nanoparticles Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown.MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma siRNAs: potential therapeutic agents against hepatitis C virus The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide Lipid-Based Nanocarriers for RNA Delivery Knocking down disease: a progress report on siRNA therapeutics Preclinical and clinical development of siRNA-based therapeutics Current prospects for RNA interference-based therapies Progress toward in vivo use of siRNAs-II Cytokines as biomarkers of nanoparticle immunotoxicity Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference Lipid-based vectors for siRNA delivery mRNA turnover rate limits siRNA and microRNA efficacy RNA Interference and Cancer Therapy Therapy for persistent HIV.Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor.Targeted comparative RNA interference analysis reveals differential requirement of genes essential for cell proliferation Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat.Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays.Polymeric nucleic acid vehicles exploit active interorganelle trafficking mechanisms.Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.

P2860

Q21090034-1EB71314-677B-42E9-BEAC-B6F4DA6E0732 Q22306293-1B507CA7-395F-42CB-82CD-FD89A10084DF Q24616751-D0B36C1F-19A8-415B-8B1B-1054A95466CA Q24626537-D88DEFF4-F7FD-40BD-9DB7-A0BF4B1C7031 Q24646644-5E31B369-9E89-49B4-B574-A4F00759E731 Q24657247-F41239F5-1F7D-4AC0-A85B-F0A35A8EE719 Q24669624-76B6ED84-D247-4253-9F37-B180591689E0 Q26766577-70C2D875-4010-4D4B-B65D-DB412BC99456 Q26782089-AF7F0FD9-F3D3-4E6E-8058-93A41FDCA829 Q26999252-406239A8-BB6E-489C-9804-04C66628D111 Q27008706-D405561A-5F16-4E07-8512-94BA024AB445 Q27024646-DC554077-E0E1-4128-AC26-E9E87E178E8A Q27313970-84843029-978C-4ACD-B88F-56098F0DFB49 Q27320938-2582548C-B3A8-4391-9E03-FF8F7774678F Q27350129-7D0A7A41-1804-4A1A-B574-E717FEB2CA32 Q27478188-6B0B7E60-7F29-4E5E-A9C5-00B6B6B9EE6E Q27485447-DCD73597-E62E-44A2-A6DF-206DC150DD46 Q27488744-3B8DDF33-F823-49B4-9593-CA4C8E0F5944 Q27694682-2E6204E5-E416-4693-A836-6A41BB7A1EE9 Q28076133-A9C79B27-5408-4505-B52E-D32F4BD8D834 Q28080706-FB09708C-9B6B-49B3-8300-B61801334821 Q28082939-EFDA9974-FC4E-409C-8C79-B11943A4545D Q28085290-E10FC77E-E2D0-4E02-8A1C-7934EB7441D5 Q28235733-20E7711F-0480-4E74-8B55-D61EB302087C Q28255877-9C05291A-3530-43CC-ADF5-5A7E95AFF71E Q28383550-B7B6C171-7EF3-45D6-9A32-57C26AFEE426 Q28390007-E29BF536-406D-4320-A671-712B15EEE468 Q28569636-19A86B05-F8DA-4565-8EEC-06E944369384 Q28828356-F8F946B3-0377-4DA0-ADD2-E9E4921C3D4C Q28914778-CC88A8E2-A10D-403D-9169-63B4596FB4F6 Q29392204-2FDB231F-5CDC-4360-942A-AAC668B5E6BA Q30386370-CF8E1089-16B9-4257-9CB6-6AE9A7279CDF Q30434397-229BCB3A-ED9F-4900-A1D7-BDBC498028C2 Q30441517-5AABADBB-C49C-4603-A3F8-39A2B656A1D2 Q30455490-091FF7A4-76A8-4BFD-BA5A-81093A55F2FE Q30494360-721A6EFC-FA0F-4F26-9E6B-82B5A6C3C521 Q30502702-0D12E9AE-8485-4019-AC40-29DBBDEF7E34 Q30524055-46BFA0BF-CC63-448C-9192-3A2182BD8AE1 Q30537017-729F2282-519E-479C-A03B-6C1A46235860 Q30624869-611C9947-97BF-4CCD-82D7-BB80D057BF7F

P2860

RNAi-mediated gene silencing in non-human primates.

http://www.wikidata.org/entity/Q53630565

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

RNAi-mediated gene silencing in non-human primates.

@en

RNAi-mediated gene silencing in non-human primates.

@nl

type

label

RNAi-mediated gene silencing in non-human primates.

@en

RNAi-mediated gene silencing in non-human primates.

@nl

prefLabel

RNAi-mediated gene silencing in non-human primates.

@en

RNAi-mediated gene silencing in non-human primates.

@nl

P1433

Q53630565-EC478C33-6D38-48E5-B17C-FA07089BA081

P1476

Q53630565-F8D0CC07-1E5C-475B-8449-A5F259188B0C

P2093

Q53630565-06F21B94-105A-4F20-AFCD-228ED41BE8FD

Q53630565-0B6F3C0F-7D5B-43AE-828B-DC9DAE781D0F

Q53630565-0E2038BD-E832-42E5-B519-04E1E67F27D5

Q53630565-12B71A67-B2B2-4ADA-9D12-18F5BB0E8291

Q53630565-15072E3C-3C0B-4E51-A2E3-33DB4D0F6F39

Q53630565-2310C84E-1545-4C28-8DEA-2DF98FC4D180

Q53630565-367B663B-9572-4C52-A900-1908D8B8E856

Q53630565-4E433CC8-6AD1-4AAB-AB96-7EF047BD301A

Q53630565-4F656BF3-7FDB-4EF5-AFC9-46A920872C6F

Q53630565-5B681AB7-D1B2-4E3F-B0BE-1BFDD3BF5747

P2860

Q53630565-05C2A616-3363-44FB-A815-7FDD5F3498CB

Q53630565-19CE687D-4C99-4276-9504-85D9F546C824

Q53630565-1AD825A4-0991-4D39-9E0D-52B8EF55B676

Q53630565-1BACAF58-04E7-48CD-92DF-166E3AC58545

Q53630565-1C9999FA-145A-42E1-8102-C9260A29B778

Q53630565-1D469E00-B5DD-4588-9B6D-149F0E74FD2F

Q53630565-251261E6-521A-456D-AF66-C2FCCBEBAFB2

Q53630565-4DD9D6B7-1658-4C2A-AEF5-817227A7E8C2

Q53630565-66DCA9C5-DA36-42DF-80F9-CEA6F4814CD2

Q53630565-731F9D66-2264-4265-AA68-237B897FFE35

P2888

Q53630565-05202248-ED90-4344-942F-E0E7DEB4753B

P304

Q53630565-BDD084BC-C910-403F-96ED-D2EEEF5364FF

P31

Q53630565-F0DC3F28-118F-4F02-8886-0EFDB3CAB1D8

P356

Q53630565-15D26083-9087-4078-A331-2B4812639C89

P407

Q53630565-028BCFDE-FD71-4D0A-BD51-7046A1DEE5F0

P433

Q53630565-130A2C96-5A08-4A09-92DE-237AD26CB687

P478

Q53630565-BCBF235E-AED3-413E-9809-D81D5D763D11

P50

Q53630565-20C4F344-09CD-4CD5-9EAF-DFD31B847F98

Q53630565-40616470-E14F-4DD3-9A01-FD546DB5479D

Q53630565-9941C2FC-9464-45F1-90C8-03AEE1F1AF5B

P577

Q53630565-1E844465-941A-4CB7-B2D4-C5EDEE43DCF9

P5875

Q53630565-BFE057C4-A80C-44C0-80C0-9054CDA5DAF6

P6179

Q53630565-932389D3-4D7F-4F1A-9AF2-69C4E48D7189

P698

Q53630565-85D6DF82-062E-44E3-9251-0627B0A1199A

P356

P1433

P1476

RNAi-mediated gene silencing in non-human primates.

@en

P2093

Adam D Judge

http://www.w3.org/2001/XMLSchema#string

Akin Akinc

http://www.w3.org/2001/XMLSchema#string

Amanda J Wheat

http://www.w3.org/2001/XMLSchema#string

Amy C H Lee

http://www.w3.org/2001/XMLSchema#string

Birgit Bramlage

http://www.w3.org/2001/XMLSchema#string

David Bumcrot

http://www.w3.org/2001/XMLSchema#string

Ed Yaworski

http://www.w3.org/2001/XMLSchema#string

Ian MacLachlan

http://www.w3.org/2001/XMLSchema#string

Ivanka Toudjarska

http://www.w3.org/2001/XMLSchema#string

James A Heyes

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

A receptor-mediated pathway for cholesterol homeostasis

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

The prospect of silencing disease using RNA interference.

Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference.

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.

P2888

P304

111-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE04688

http://www.w3.org/2001/XMLSchema#string

P407

P433

7089

http://www.w3.org/2001/XMLSchema#string

P478

441

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Vornlocher

Victor Koteliansky

P577

2006-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7212994

http://www.w3.org/2001/XMLSchema#string

P6179

1026190446

http://www.w3.org/2001/XMLSchema#string

P698

16565705

http://www.w3.org/2001/XMLSchema#string